RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-8.79%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$4.42B
AUM Growth
+$4.42B
(-10%)
Cap. Flow
+$162M
Cap. Flow
% of AUM
3.66%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
73
New
3
Increased
12
Reduced
3
Closed
14
Top Buys
| 1 |
CureVac
CVAC
|
$85.4M |
| 2 |
Vaxcyte
PCVX
|
$53.7M |
| 3 |
Mineralys Therapeutics
MLYS
|
$49.8M |
| 4 |
Pliant Therapeutics
PLRX
|
$46.9M |
| 5 |
Geron
GERN
|
$40.4M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
$83.8M |
| 2 |
Akero Therapeutics
AKRO
|
$52.6M |
| 3 |
Enliven Therapeutics
ELVN
|
$24.7M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
$21.8M |
| 5 |
DALS
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
|
$15M |
Sector Composition
| 1 | Healthcare | 99.99% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $746M | 16.89% | 6,957,179 | – | – |
|
|
2
Vaxcyte
PCVX
$4B
| $273M | 6.19% | 7,291,254 +1,433,795 | +24% | +$53.7M |
|
|
DICE
3
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $225M | 5.1% | 7,856,612 +1,007,701 | +15% | +$28.9M |
|
4
89bio
ETNB
$1.34B
| $174M | 3.94% | 11,416,948 +2,461,538 | +27% | +$37.5M |
|
|
JBIO
5
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $167M | 3.77% | 8,263,982 | – | – |
|
6
Biogen
BIIB
$19.4B
| $148M | 3.35% | 532,892 | – | – |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $127M | 2.87% | 6,317,990 | – | – |
|
8
Cytek Biosciences
CTKB
$527M
| $123M | 2.78% | 13,381,054 | – | – |
|
9
Vor Biopharma
VOR
$250M
| $122M | 2.77% | 22,748,880 | – | – |
|
10
Legend Biotech
LEGN
$6.41B
| $117M | 2.66% | 2,436,223 | – | – |
|
11
Tyra Biosciences
TYRA
$675M
| $116M | 2.63% | 7,236,454 | – | – |
|
12
Janux Therapeutics
JANX
$1.37B
| $105M | 2.38% | 8,670,644 | – | – |
|
13
PepGen
PEPG
$38M
| $99.5M | 2.25% | 8,131,952 | – | – |
|
14
Avidity Biosciences
RNA
$5.99B
| $98.5M | 2.23% | 6,416,998 +962,465 | +18% | +$14.8M |
|
15
Rhythm Pharmaceuticals
RYTM
$6.85B
| $98.4M | 2.23% | 5,516,067 | – | – |
|
16
Day One Biopharmaceuticals
DAWN
$769M
| $94.1M | 2.13% | 7,040,622 | – | – |
|
|
BLU
17
DELISTED
BELLUS Health Inc.
BLU
| $91M | 2.06% | 12,643,574 +191,000 | +2% | +$1.38M |
|
|
18
CureVac
CVAC
$1.21B
| $85.4M | 1.93% | +12,245,955 | New | +$85.4M |
|
|
IMGN
19
DELISTED
Immunogen Inc
IMGN
| $83.9M | 1.9% | 21,853,958 | – | – |
|
20
Wave Life Sciences
WVE
$1.53B
| $74.5M | 1.69% | 17,202,009 | – | – |
|
|
INBX
21
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $72.7M | 1.65% | 3,853,867 | – | – |
|
|
22
Geron
GERN
$893M
| $68.5M | 1.55% | 31,544,806 +18,614,095 | +144% | +$40.4M |
|
23
Cogent Biosciences
COGT
$1.69B
| $64.7M | 1.47% | 5,999,481 | – | – |
|
24
Celldex Therapeutics
CLDX
$1.47B
| $62.4M | 1.41% | 1,734,972 -340,028 | -16% | -$12.2M |
|
25
Acrivon Therapeutics
ACRV
$42.2M
| $61M | 1.38% | 4,810,508 | – | – |
|